Early results of @entity619 implant, ranibizumab, and triamcinolone in XXXX due to branch @entity2994 .

@entity1 @entity2995 @entity231 @entity9170 @entity2994 @entity1103 @entity619 @entity1020
PURPOSE: To compare the short-term results of the efficacy and safety of @entity619 intravitreal implant (DEX), ranibizumab (RAN), and intravitreal @entity2995 (IVTA) in @entity1103 secondary to branch @entity2994 (BRVO). METHODS: One eye each of 32 @entity1 who were treated with intravitreal injections for @entity1103 secondary to BRVO was studied. This retrospective study included 3 groups. The @entity1 received DEX in group 1 (n = 11), RAN in group 2 (n = 11), and IVTA in group 3 (n = 10). Data were collected before and after the injections at the first and third months. Best-corrected visual acuity (BCVA), @entity1020 ( @entity1020 ), and intraocular pressure (IOP) were analyzed statistically. RESULTS: The median duration of the follow-up was 3.0 months in overall groups. The BCVA increased significantly in all groups (p = 0.018, p = 0.034, p = 0.014, respectively). The @entity1020 increased significantly in groups 1 and 3 (p = 0.02, plt;0.001, respectively), but not in group 2 (p = 0.14). The IOP increased significantly in groups 1 and 3 (p = 0.05, plt;0.001, respectively). Antiglaucomatous treatment was required only in group 3. @entity231 developed in 2 @entity1 (20%) in group 3 and surgery was required. CONCLUSIONS: Although RAN was the safest among the 3 agents, @entity9170 and IVTA reduced @entity1020 more than RAN, while significant improvement was achieved in BCVA in all groups. All 3 agents can be effectively used in the treatment of @entity1103 due to BRVO.
